Renal cell growth medium

Renal cell growth medium
Product Description

Lonza Biologics Inc offers wide range of pharma products and services which includes renal cell growth medium. It belongs to primary and adult stem cells, human primary cells and media, renal cells (normal & diseased) & media services & products category. It is is formulated for the growth of renal mesangial cells. MsGM™ contains 5% serum. It includes basal medium - contains no growth factors cytokines, or supplements, singlequots™ kit - growth factors, cytokines, and supplements, bulletkit™ - basal medium and singlequots™ kit packaged together.

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since

More Products from Lonza Capsules & Health Ingredients (52)

  • Mouse brain mixed astrocytes

    Product Mouse brain mixed astrocytes

    Lonza Biologics Inc offers wide range of pharma products and services which includes mouse brain mixed astrocytes. It belongs to primary and adult stem cells, animal cells & media, mouse neural cells & media services and products category. Applications: transfection, electrophysiological properties, neur...
  • Mouse brain striatum neurons

    Product Mouse brain striatum neurons

    Lonza Biologics Inc offers wide range of pharma products and services which includes mouse brain striatum neurons. It belongs to primary and adult stem cells, animal cells & media, mouse neural cells & media services and products category. Applications: transfection, electrophysiological properties, neuro...
  • Mouse embryonic fibroblasts

    Product Mouse embryonic fibroblasts

    Lonza Biologics Inc offers wide range of pharma products and services which includes mouse embryonic fibroblasts. It belongs to primary and adult stem cells, animal cells & media, mouse embryonic fibroblasts services and products category. It is dissociated from CD-1 mouse embryos, expanded by culture and ...
  • Multi purpose media

    Product Multi purpose media

    Lonza Biologics Inc offers wide range of pharma products and services which includes multi purpose media. It belongs to upstream serum-free media and feed formulations services and products category. Contact us for more information.
  • Mycoplasma detection & removal

    Product Mycoplasma detection & removal

    Lonza Biologics Inc offers wide range of pharma products and services which includes mycoplasma detection & removal. It belongs to cell culture products category. It includes background on mycoplasma contamination, mycoalert™ plus mycoplasma detection kit, mycoalert™ mycoplasma detection kit, myc...
  • Rat microglia

    Product Rat microglia

    Lonza Biologics Inc offers wide range of pharma products and services which includes rat microglia. It belongs to primary and adult stem cells, animal cells & media, rat neural cells and media. It is is one of the glial cell types in the CNS. It is an important integral component of neuro-glial cell network.
  • Retinal cells & medium

    Product Retinal cells & medium

    Lonza Biologics Inc offers wide range of pharma products and services which includes retinal cells & medium. It includes clonetics™ human rpe cells, rtegm™ retinal pigment epithelial cell growth medium. Appplication: age related macular, degeneration, retinistis pigmentosa, gene expression, cel...
  • Richter's cm medium with l-glutamine

    Product Richter's cm medium with l-glutamine

    Lonza Biologics Inc offers wide range of pharma products and services which includes richter's cm medium with l-glutamine. It belongs to cell culture products, classical media, other media products category. It is a complex formula used to supplement hybridoma medium.
  • Rpmi 1640 with/without l-glutamine

    Product Rpmi 1640 with/without l-glutamine

    Lonza Biologics Inc offers wide range of pharma products and services which includes rpmi 1640 with l-glutamine. It belongs to cell culture products classical media rpmi services and products category. It It can be used for suspension and monolayer mammalian cultures.
  • Sample bag drawings

    Product Sample bag drawings

    Lonza Biologics Inc offers wide range of pharma products and services which includes sample bag drawings.It belongs to downstream products and services category. It includes polyethylene film in a 2-web configuration, versatility in connectivity, automated sealing process, carrier handles.
  • Sertoli cells & medium

    Product Sertoli cells & medium

    Lonza Biologics Inc offers wide range of pharma products and services which includes sertoli cells & medium. It belongs to primary and adult stem cells, human primary cells and media services and products category. It is a highly specialized and essential for maintenance of testicular homeostasis and male ...
  • Service plan options for readers and pyrotec™

    Product Service plan options for readers and pyrotec™

    Lonza Biologics Inc offers wide range of pharma products and services which includes service plan options for readers and pyrotec™. It belongs to pharma & biotech complementary business solutions services and products category. It includes elx808™ absorbance plate reader, flx800™ fluorescenc...

Lonza Capsules & Health Ingredients resources (6)

  • News CPHI North America 2023 – From the Floor

    Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 
  • Video Lonza

    Enabling a healthier world.
  • News Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing

    The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies
  • Video Making a Splash in the US Market: How PBPK Modeling is Playing a Central Role in Risk Reduction in Early Drug Development

    Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.
  • News Lonza Switzerland site to undergo expansion of microbial development capabilities

    The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects
  • News Lonza boosts exosome capability with Codiak BioSciences facility acquisition

    The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies